News Sentiment

CRVS sentiment intelligence

Corvus Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.67 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+2.9% over one week, +31.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Corvus Pharmaceuticals (CRVS) Proxy filing Summary

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 2.9% Price confirming higher
Trend fit Trend inactive 31.3% over four weeks
Fair value 162.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 8
TradingView 7
simplywall.st 5
Sahm 4
TradingKey 4
Quartr 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 20
Analyst action 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Sahm Direct company coverage

Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness

Corvus Pharmaceuticals (CRVS) has seen significant short-term share price declines despite strong long-term gains, leading to investor questions about its valuation. While a narrative fair value of $35 suggests it's 65.5% undervalued, the P/B ratio at 4.2x (compared to an industr

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 11:39
Source
Sahm
Stock Titan Direct company coverage

Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust

Dr. Richard A. Miller, President and CEO of Corvus Pharmaceuticals, Inc. (CRVS), reported indirect open-market purchases of 6,932 shares of the company's common stock through the Miller-Horning Family Trust. These transactions, which occurred on May 18, 2026, involved purchases a

Tone
Negative 42/100
Event
Market update
Published
20 May 2026 20:40
Source
Stock Titan
Associated Press Direct company coverage

Corvus: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
07 May 2026 20:44
Source
Associated Press